The FDA granted the designation to brentuximab vedotin (Adcetris) for this indication in combination with cyclophosphamide, doxorubicin, and prednisone.
Top news of the day from across the health care landscape.
Direct-acting antivirals are a costly but highly-effective class of drugs for the treatment of hepatitis C that can cure most cases.
Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.
The new formulary will allow health plans to cover lower list price products, such as new authorized alternatives to brand-name medications.
Top news of the day from across the health care landscape.
One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.